Gomi, M.; Nakayama, Y.; Sakurai, Y.; Oyama, R.; Iwasaki, K.; Doi, M.; Liu, Y.; Hori, M.; Watanabe, H.; Hashimoto, K.;
et al. Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis. Pharmaceuticals 2023, 16, 1270.
https://doi.org/10.3390/ph16091270
AMA Style
Gomi M, Nakayama Y, Sakurai Y, Oyama R, Iwasaki K, Doi M, Liu Y, Hori M, Watanabe H, Hashimoto K,
et al. Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis. Pharmaceuticals. 2023; 16(9):1270.
https://doi.org/10.3390/ph16091270
Chicago/Turabian Style
Gomi, Masaki, Yuka Nakayama, Yu Sakurai, Ryotaro Oyama, Koki Iwasaki, Mizuki Doi, Yi Liu, Mizuho Hori, Himeka Watanabe, Kohei Hashimoto,
and et al. 2023. "Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis" Pharmaceuticals 16, no. 9: 1270.
https://doi.org/10.3390/ph16091270
APA Style
Gomi, M., Nakayama, Y., Sakurai, Y., Oyama, R., Iwasaki, K., Doi, M., Liu, Y., Hori, M., Watanabe, H., Hashimoto, K., Tanaka, H., Tange, K., Nakai, Y., & Akita, H.
(2023). Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis. Pharmaceuticals, 16(9), 1270.
https://doi.org/10.3390/ph16091270
